These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 2971433)

  • 1. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
    Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
    Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
    Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI
    Cancer Res; 1988 Nov; 48(22):6597-602. PubMed ID: 2902918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a lipid-like cytotoxin from human CD16+ natural killer cells.
    Cosentino LM; Cathcart MK
    Cancer Res; 1989 Dec; 49(23):6662-9. PubMed ID: 2531033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
    Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes.
    Faure F; Jitsukawa S; Triebel F; Hercend T
    J Immunol; 1988 Mar; 140(5):1372-9. PubMed ID: 2964471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
    Fuchshuber PR; Lotzová E; Pollock RE
    Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
    Schwarz RE; Hiserodt JC
    J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
    Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH
    Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.